Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Breast
Study Phase
Phase 3
Study Completion Date
2007-01
NCT00003519Uploaded 04-26-2019
Access via NCI by Request
PDS UID: nci-data-380
Phase III Study of Adriamycin/Taxotere Versus Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer
Provider Information
Provider Data DescriptionThis dataset contains the analysis data for the MetaSite BreastTM score analysis (n=600) published in PMID 29138761 with a subset of cases from the parent trial NCT00003519.
SponsorEastern Cooperative Oncology Group
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating women with breast cancer who have undergone surgery to remove the tumor.
ConditionsBreast Cancer
Intervention TypeDrug: cyclophosphamide
Drug: docetaxel
Drug: doxorubicin hydrochloride
Drug(s)N/A
Total Enrolled2778
RandomizationRandomized
Blinding MethodN/A
Arms InterventionN/A
Secondary IDE2197
PubMed (PMID)18487567
18678838
Collaborator(s)National Cancer Institute (NCI)
SWOG Cancer Research Network
North Central Cancer Treatment Group
Cancer and Leukemia Group B
Region(s)United States
Age Range18 Years to 120 Years (ADULT, OLDER_ADULT)
Files: NCT00003519-D1
Data DictionaryNCT00003519-D1-Data-Dictionary.pdf
DATANCT00003519-D1-Dataset.csv
OTHERREADME.pdf
© 2024 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use